Signal Pharma to develop new treatments for major diseases

Published: 12-Mar-2012
Research & Development Cardiovascular Pharmaceutical

Aberdeen University spin out will focus on breast cancer, heart failure, diabetes and chronic pain

The University of Aberdeen is working with Scottish entrepreneur Dr Derek Douglas CBE to spin out a company that will develop new drugs to treat breast cancer, heart failure, diabetes and chronic pain.

Signal Pharma will be the first company to be spun out from the University’s Kosterlitz Centre for Therapeutics, which is focused on translating biological innovation into new ways of treating, diagnosing and understanding diseases.

The founders of the company are pharmacology expert Professor Ruth Ross and Dr Iain Greig, a medicinal chemist who helped found another University spin out that is developing drugs to treat rheumatoid arthritis. They have joined forces with cardiologist Professor Michael Frenneaux, and molecular imaging expert Professor Matteo Zanda. Dr Derek Douglas, chairman and ceo of Adam Smith Ltd is providing financial and business acumen, while Dr Michael Wyllie, founder and director Global Pharma Consulting, will provide drug development expertise.

Sigma Pharma will develop a portfolio of four drug discovery projects based on new pathways and targets identified by the University of Aberdeen scientists.

The firm is seeking to raise £1.5m to develop these projects over a period of three years.

Prof Ross, who is also director of the University’s Kosterlitz Centre, said: ‘The creation of Signal Pharma is a great opportunity to generate both medical and economic benefits based on the world class biomedical research of discoveries of the University of Aberdeen.’

Dr Greig added: ‘It is particularly satisfying to see ideas that we have worked on for many years reaching the next stage of the development process, which we hope will eventually lead to new drugs that give real benefits to the patients, saving lives and reducing suffering.’

See more

You may also like

Research & Development

New company created to develop novel technology to treat diabetes

Read more
Islexa technology has the potential to bring islet transplant therapy to treat type 1 diabetes

Trending Articles

  1. FDA and EMA issue guiding principles for AI in drug development The set of ten principles gives broad guidance on AI use in evidence generation and monitoring across all phases of a medicine, from early research and clinical trials to manufacturing and safety monitoring
  2. Enara Bio expands Boehringer Ingelheim partnership as DARKFOX programme moves toward the clinic Enara Bio has entered 2026 with renewed momentum after Boehringer Ingelheim licensed additional Dark Antigen targets under their oncology collaboration. The company is also continuing to expand its EDAPT discovery platform
  3. Studies on HIV and TB reveal tradeoffs for both viruses and immune system in race to survive Research teams have identified mechanisms by which HIV can evade lenacapavir, at the cost of the virus's reproduction and how the immune system can use bacteria to protect against infection — until TB evolved to take advantage
  4. One in ten Britons are using or interested in using GLP-1s for weight loss, according to new research GLP-1 use and interest was more prevalent among women, as well as those who reported difficulties with their finances or who had experienced psychological distress within the previous month
  5. FairJourney Bio launches cryo-EM services to support antibody discovery and biologics design The new offering at the company's San Diego laboratories provides high-resolution structural insights to accelerate antibody discovery, selection and optimisation across the biologics R&D pipeline

Upcoming event

Pharmapack

21–22 January 2026 | Exhibition | Paris, France See all

You may also like

Research & Development

New company created to develop novel technology to treat diabetes

Islexa technology has the potential to bring islet transplant therapy to treat type 1 diabetes
Research & Development

Aberdeen University wins £5.1m grant to tackle fungal infections

New strategies needed to combat life-threatening invasive fungal infections
Research & Development

Drug discovery centre to open in Aberdeen

Kosterlitz Centre for Therapeutics will take ideas from bench to bedside
Manufacturing

Cellistic launches new iPSC-based GMP platforms to boost cell therapy development

Echo-T, Echo-Cardio, and Echo-Endothelial enable scalable immuno-oncology and regenerative therapies
Research & Development

FDA and EMA issue guiding principles for AI in drug development

The set of ten principles gives broad guidance on AI use in evidence generation and monitoring across all phases of a medicine, from early research and clinical trials to manufacturing and safety monitoring
Drug Delivery

Bio-Sourcing and Zerion Pharma secure Eurostars funding to develop HER2 oral monoclonal antibody

The pair have been awarded a €1.3m Eurostars grant to develop an oral formulation of the anti-HER2 monoclonal antibody trastuzumab for breast cancer, combining Bio-Sourcing’s BioMilk platform with Zerion’s Dispersome technology to advance the candidate through preclinical development
Research & Development

FairJourney Bio launches cryo-EM services to support antibody discovery and biologics design

The new offering at the company's San Diego laboratories provides high-resolution structural insights to accelerate antibody discovery, selection and optimisation across the biologics R&D pipeline
Subscribe now